Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety of selexipag in addition to the infusion of prost...
Main Authors: | Mizuki Momoi, Takahiro Hiraide, Yoshiki Shinya, Hiromi Momota, Shogo Fukui, Michiyuki Kawakami, Keiichi Fukuda, Masaharu Kataoka |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007122000144 |
Similar Items
-
Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
by: Elizabeth Colglazier, et al.
Published: (2022-10-01) -
The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report
by: Akram Khan, et al.
Published: (2023-01-01) -
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
by: Hardin EA, et al.
Published: (2016-11-01) -
Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
by: Jenna M. Faircloth, et al.
Published: (2023-03-01) -
Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
by: Jenna M. Faircloth, et al.
Published: (2023-08-01)